Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sangamo Therapeutics 501 Canal Blvd Richmond CA 94804 USA

www.sangamo.com Employees: 183 P: 510-970-6000 F: 510-236-8951

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.

Key Statistics

Overview:

Market Capitalization, $K 151,490
Enterprise Value, $K 109,570
Shares Outstanding, K 336,495
Annual Sales, $ 57,800 K
Annual Net Income, $ -97,940 K
Last Quarter Sales, $ 580 K
Last Quarter Net Income, $ -34,930 K
EBIT, $ -109,030 K
EBITDA, $ -99,940 K
60-Month Beta 1.29
% of Insider Shareholders 4.10%
% of Institutional Shareholders 56.92%
Float, K 322,699
% Float 95.90%
Short Interest 19,796
Short Float 5.88%
Short Volume Ratio 0.35

Growth:

1-Year Return -63.54%
3-Year Return -87.83%
5-Year Return -97.19%
5-Year Revenue Growth -43.57%
5-Year Earnings Growth 42.35%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 11/06/25
Next Earnings Date 03/16/26
Earnings Per Share ttm -0.44
EPS Growth vs. Prev Qtr -37.50%
EPS Growth vs. Prev Year -375.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SGMO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -813.95%
Return-on-Assets % -116.48%
Profit Margin % -169.45%
Debt/Equity 0.00
Price/Sales 3.34
Price/Cash Flow N/A
Price/Book 22.23
Book Value/Share 0.02
Interest Coverage -0.95
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar